Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours.
Kruse B, Buzzai AC, Shridhar N, Braun AD, Gellert S, Knauth K, Pozniak J, Peters J, Dittmann P, Mengoni M, van der Sluis TC, Höhn S, Antoranz A, Krone A, Fu Y, Yu D, Essand M, Geffers R, Mougiakakos D, Kahlfuß S, Kashkar H, Gaffal E, Bosisio FM, Bechter O, Rambow F, Marine JC, Kastenmüller W, Müller AJ, Tüting T. Kruse B, et al. Among authors: bosisio fm. Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14. Nature. 2023. PMID: 37316667 Free PMC article.
Single-cell molecular profiling using ex vivo functional readouts fuels precision oncology in glioblastoma.
Panovska D, Nazari P, Cole B, Creemers PJ, Derweduwe M, Solie L, Van Gassen S, Claeys A, Verbeke T, Cohen EF, Tolstorukov MY, Saeys Y, Van der Planken D, Bosisio FM, Put E, Bamps S, Clement PM, Verfaillie M, Sciot R, Ligon KL, De Vleeschouwer S, Antoranz A, De Smet F. Panovska D, et al. Among authors: bosisio fm. Cell Mol Life Sci. 2023 May 12;80(6):147. doi: 10.1007/s00018-023-04772-1. Cell Mol Life Sci. 2023. PMID: 37171617
Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma.
Frias A, Di Leo L, Antoranz A, Nazerai L, Carretta M, Bodemeyer V, Pagliuca C, Dahl C, Claps G, Mandelli GE, Andhari MD, Pacheco MP, Sauter T, Robert C, Guldberg P, Madsen DH, Cecconi F, Bosisio FM, De Zio D. Frias A, et al. Among authors: bosisio fm. J Immunother Cancer. 2023 Mar;11(3):e006389. doi: 10.1136/jitc-2022-006389. J Immunother Cancer. 2023. PMID: 36868570 Free PMC article.
GSNOR deficiency promotes tumor growth via FAK1 S-nitrosylation.
Rizza S, Di Leo L, Pecorari C, Giglio P, Faienza F, Montagna C, Maiani E, Puglia M, Bosisio FM, Petersen TS, Lin L, Rissler V, Viloria JS, Luo Y, Papaleo E, De Zio D, Blagoev B, Filomeni G. Rizza S, et al. Among authors: bosisio fm. Cell Rep. 2023 Jan 31;42(1):111997. doi: 10.1016/j.celrep.2023.111997. Epub 2023 Jan 18. Cell Rep. 2023. PMID: 36656716 Free article.
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop.
Hua Y, Vella G, Rambow F, Allen E, Martinez AA, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, Floris G, Laoui D, Hollmén M, Lambrechts D, Merchiers P, Marine JC, Schlenner S, Bergers G. Hua Y, et al. Among authors: bosisio fm. Cancer Cell. 2023 Jan 9;41(1):226. doi: 10.1016/j.ccell.2022.12.006. Cancer Cell. 2023. PMID: 36626867 Free article. No abstract available.
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.
Nazerai L, Willis SC, Yankilevich P, Di Leo L, Bosisio FM, Frias A, Bertolotto C, Nersting J, Thastrup M, Buus S, Thomsen AR, Nielsen M, Rohrberg KS, Schmiegelow K, De Zio D. Nazerai L, et al. Among authors: bosisio fm. Oncoimmunology. 2022 Dec 17;12(1):2158610. doi: 10.1080/2162402X.2022.2158610. eCollection 2023. Oncoimmunology. 2022. PMID: 36545256 Free PMC article.
Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop.
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, Floris G, Laoui D, Hollmén M, Lambrechts D, Merchiers P, Marine JC, Schlenner S, Bergers G. Hua Y, et al. Among authors: bosisio fm. Cancer Cell. 2022 Dec 12;40(12):1600-1618.e10. doi: 10.1016/j.ccell.2022.11.002. Epub 2022 Nov 23. Cancer Cell. 2022. PMID: 36423635 Free PMC article.
GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide.
Parik S, Fernández-García J, Lodi F, De Vlaminck K, Derweduwe M, De Vleeschouwer S, Sciot R, Geens W, Weng L, Bosisio FM, Bergers G, Duerinck J, De Smet F, Lambrechts D, Van Ginderachter JA, Fendt SM. Parik S, et al. Among authors: bosisio fm. Front Oncol. 2022 Sep 23;12:988872. doi: 10.3389/fonc.2022.988872. eCollection 2022. Front Oncol. 2022. PMID: 36338708 Free PMC article.
52 results